Marshall Wace North America L.P. acquired a new stake in Viewray Inc (NASDAQ:VRAY) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 249,615 shares of the company’s stock, valued at approximately $1,844,000. Marshall Wace North America L.P. owned 0.26% of Viewray at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in VRAY. American International Group Inc. raised its holdings in Viewray by 3.9% in the fourth quarter. American International Group Inc. now owns 41,576 shares of the company’s stock worth $252,000 after purchasing an additional 1,573 shares during the period. TD Asset Management Inc. raised its holdings in Viewray by 4.3% in the first quarter. TD Asset Management Inc. now owns 60,167 shares of the company’s stock worth $445,000 after purchasing an additional 2,500 shares during the period. NumerixS Investment Technologies Inc raised its holdings in Viewray by 90.6% in the fourth quarter. NumerixS Investment Technologies Inc now owns 6,100 shares of the company’s stock worth $34,000 after purchasing an additional 2,900 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in shares of Viewray by 4.3% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 74,440 shares of the company’s stock worth $550,000 after acquiring an additional 3,090 shares in the last quarter. Finally, Pennsylvania Trust Co increased its position in shares of Viewray by 2.5% during the first quarter. Pennsylvania Trust Co now owns 129,441 shares of the company’s stock worth $957,000 after acquiring an additional 3,100 shares in the last quarter.
Shares of Viewray stock traded down $0.02 during midday trading on Friday, hitting $9.17. 698,264 shares of the company traded hands, compared to its average volume of 821,755. Viewray Inc has a 12 month low of $4.86 and a 12 month high of $13.21. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.21 and a current ratio of 4.28. The stock has a market capitalization of $889.06 million, a PE ratio of -9.36 and a beta of 0.79. The business has a fifty day simple moving average of $8.67.
In other news, insider James F. Dempsey sold 5,146 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $8.63, for a total value of $44,409.98. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 15.48% of the stock is currently owned by insiders.
Several analysts have weighed in on the stock. Piper Jaffray Companies dropped their price objective on shares of Cactus from $42.00 to $34.00 and set an “overweight” rating for the company in a research note on Tuesday, June 18th. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Monday, May 13th. TheStreet cut shares of Viewray from a “c-” rating to a “d” rating in a research note on Friday, May 3rd. Zacks Investment Research upgraded shares of SCHNEIDER ELEC /ADR from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Friday, July 5th. Finally, BidaskClub lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Viewray has an average rating of “Buy” and a consensus price target of $13.05.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Further Reading: Dividend Achievers
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.